EUVIMEDEUVIMED entdecken
Crossref

Structure-activity relationship of dihydropyridines for rhabdomyosarcoma

Shefali Chauhan, Andrew D Woods, Narendra Bharathy, Xiaolei Lian, Cora A Ricker, Amy Mantz, William J Zuercher, Lisa H Price, Michael J Morton, Eric Durrant, Stéphane Y Corbel, Srinath C Sampath und 3 weitere

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.04.114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Shefali Chauhan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA. Electronic address: shefali@cc-tdi.org. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Dihydropyridines. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Childhood muscle-related cancer rhabdomyosarcoma is a rare disease with a 50-year unmet clinical need for the patients presented with advanced disease. The rarity of ∼350 cases per year in North America generally diminishes the viability of large-scale, pharmaceutical industry driven drug development efforts for rhabdomyosarcoma. In this study, we performed a large-scale screen of 640,000 compounds to identify the dihydropyridine (DHP) class of anti-hypertensives as a priority compound hit. A structure-activity relationship was uncovered with increasing cell growth inhibition as side chain length increases at the ortho and para positions of the parent DHP molecule. Growth inhibition was consistent across n = 21 rhabdomyosarcoma cell line models. Anti-tumor activity in vitro was paralleled by studies in vivo. The unexpected finding was that the action of DHPs appears to be other than on the DHP receptor (i.e., L-type voltage-gated calcium channel). These findings provide the basis of a medicinal chemistry program to develop dihydropyridine derivatives that retain anti-rhabdomyosarcoma activity without anti-hypertensive effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaDihydropyridinesHumansChildCalcium Channel BlockersStructure-Activity RelationshipAntihypertensive AgentsCalcium Channels, L-Type

Stichwörter der Autor:innen

AzelnidipineDihydropyridineFelodipineRhabdomyosarcomaSarcoma

Substanzen

Calcium Channel BlockersAntihypertensive AgentsCalcium Channels, L-TypeDihydropyridines

Autor:innen und Institutionen

  • Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA. Electronic address: shefali@cc-tdi.org.
  • Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA.
  • ApconiX Ltd, Alderley Park, Nether Alderley, Cheshire, SK10 4TG, UK.
  • Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA.
  • Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA. Electronic address: charles@cc-tdi.org.

Zitieren

APA

Chauhan, S., Woods, A. D., Bharathy, N., Lian, X., Ricker, C. A., Mantz, A., Zuercher, W. J., Price, L. H., Morton, M. J., Durrant, E., Corbel, S. Y., Sampath, S. C., Sampath, S. C., Joslin, J., & Keller, C. (2023). Structure-activity relationship of dihydropyridines for rhabdomyosarcoma. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.04.114

Vancouver

Chauhan S, Woods AD, Bharathy N, Lian X, Ricker CA, Mantz A, et al. Structure-activity relationship of dihydropyridines for rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.04.114

BibTeX
@article{Chauhan2023,
  author = {Chauhan, Shefali and Woods, Andrew D and Bharathy, Narendra and Lian, Xiaolei and Ricker, Cora A and Mantz, Amy and Zuercher, William J and Price, Lisa H and Morton, Michael J and Durrant, Eric and Corbel, Stéphane Y and Sampath, Srinath C and Sampath, Srihari C and Joslin, John and Keller, Charles},
  title = {Structure-activity relationship of dihydropyridines for rhabdomyosarcoma},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.04.114}
}
Kostenlos starten →